Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

of Actavis Group. 

Actavis Specialty Brands R&D investment in the fourth quarter increased $23.8 million due to higher in-licensing costs and increased costs related to our biosimilar product development.  Actavis Specialty Brands selling and marketing expenses decreased by $1.2 million to $45.3 million in the fourth quarter, primarily due to lower promotional spending in the U.S., partially offset by higher commercial spending in Canada.

For the full year 2012, Actavis Specialty Brands segment net revenue increased 9 percent to $482.4 million, due to increased sales of Generess Fe® which was launched in the second quarter of 2011 and sales growth for key promoted products including  Rapaflo® and Crinone® and the addition of  Kadian®.

Actavis Specialty Brands segment adjusted gross margin for the full year 2012 was 76.1 percent, compared to 78.7 percent in 2011 as a result of product mix. Anda Distribution Segment InformationThree Months EndedTwelve Months EndedDecember 31, December 31,(Unaudited; $ in millions)2012201120122011Net revenue

$
203.9$
251.4$
986.4$
776.2Operating expenses:Cost of sales

168.1214.6846.6652.7Selling and marketing

21.320.889.877.2Segment contribution

$
4.5$
.0$
50.0$
46.3Segment margin

7.1%6.4%5.1%6.0%Gross profit

$
35.8$
36.8$
39.8$
23.5Gross margin

17.6%14.6%14.2%15.9%Anda Distribution segment net revenue for the fourth quarter 2012 decreased 19 percent to $203.9 million compared to $251.4 million in the fourth quarter 2011 due to lower chain sales offset by new product launches. Anda Distribution segment revenue consists only of sales of third-party products and excludes sales of Actavis' brand and generic products.

Anda Distribution segment gross margin increased 300 basis points to 17.6 percent in the fourth quarter 2012, prim
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/24/2014)... often coexist with the negative and stressful outcomes for ... diagnosed with a life-limiting illness, says a recent study ... , While the challenges are numerous and life-changing and ... participated in the Waterloo-led research reported positive outcomes as ... appear in the most recent issue of the ...
(Date:4/24/2014)... in the new Institute for Biomedical Sciences at ... million federal grant to develop novel therapeutics against ... from the Eunice Kennedy Shriver National Institute Of ... Institutes of Health will support Plemper,s drug development ... least one distinct alternative compound. , Infections by ...
(Date:4/24/2014)... Ill. It is better to give than to receive ... giving, a new study suggests. , The study found that ... as giving their money to family members, are less likely ... from taking risks or keeping the money for themselves. , ... the National Academy of Sciences . , The study focused ...
(Date:4/24/2014)... influenza pH1N1 virus caused the first flu pandemic in ... 2009 and killed more than 50 people in the ... during flu epidemics (winter/spring seasons). , Infections with ... illnesses. World Health Organization has recommended Tamiflu for treatment ... of this drug is that it targets viral proteins ...
(Date:4/23/2014)... say clinical trials for a new experimental drug ... promising. Patients treated with CPX-351, a combination of ... better responses than patients treated with the standard ... leukemia is an aggressive blood cancer with very ... patients," explained Jeffrey Lancet, M.D., senior member of ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... LANSING, Mich. To tackle the growing number of psychiatric cases ... team of Michigan State University doctors from the colleges of ... from across the state via video conference. , On ... see up to 10 patients each from as far away ...
... study says , , MONDAY, Oct. 27 (HealthDay News) -- ... coronary conditions, might reduce the effect of the clot-preventing ... blockers appear to inactivate an enzyme essential for the ... published online Oct. 28 in the Journal of ...
... Treatment, ST. LOUIS, Oct. 27 Leading ... deliver radioactive seed therapy,in the prostate. The innovative ... the prostate during procedures. With the gland stabilized,physicians ... to map,and confirm placement of radiation., Unveiled ...
... Study found desires remained essentially unchanged over 3-year period ... declines in either mental or physical health, most senior ... want their end-of-life care to be when the time ... that despite observing an overall stability in patient perspective, ...
... Oct. 27 SpectraCell Laboratories, Inc.,announced that ... facilities. Recently,SpectraCell occupied a 20,000 sq. ft. ... 2005. The planned expansion added a second ... campus. The new $3.5 million facility houses,SpectraCell,s ...
... an initial,step in the creation of a wellness ... it has acquired HealthMedia, Inc., a,privately held company ... change interventions. Terms of the transaction were not,disclosed., ... to,effectively emulate a health coach via the web. ...
Cached Medicine News:Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2Health News:Seniors Tend to Stick With End-of-Life Care Preferences 2Health News:Seniors Tend to Stick With End-of-Life Care Preferences 3Health News:SpectraCell Laboratories Expands Operations in New Facility 2Health News:Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc. 2
PremierEdge™ Tunnel Knives....
PremierEdge™ Clear Cornea Knives....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 600....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 550 to 700....
Medicine Products: